Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa-Clofarabine-Busulfan Conditioning for Allo SCT
NCT00857389Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2009
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, clofarabine and busulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL) and 5 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Survival Rate at 100 Days Post-transplant. Started Mar 2009; status: completed.
02
Drugs
thiotepaclofarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00857389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857389.